#BEGIN_DRUGCARD DB02237

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
34612-38-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C24H42O21

# Chemical_IUPAC_Name:
(2S,3S,4R,5R,6S)-2-{[(2S,3S,4R,5R,6S)-6-{[(2S,3S,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-{[(2S,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Maltotetraose

# HET_ID:
MTT

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C24H42O21/c25-1-5-9(29)10(30)15(35)22(40-5)44-19-7(3-27)42-24(17(37)12(19)32)45-20-8(4-28)41-23(16(36)13(20)33)43-18-6(2-26)39-21(38)14(34)11(18)31/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15-,16+,17+,18+,19+,20+,21+,22-,23-,24-/m0/s1

# InChI_Key:
InChIKey=LUEWUZLMQUOBSB-OUBHKODOSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C02052

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2237

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
666.5777

# Molecular_Weight_Mono:
666.221858406

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1QI3

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.7

# Predicted_LogS:
-0.28

# Predicted_Water_Solubility:
3.50e+02 g/l

# Primary_Accession_No:
DB02237

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936329

# PubChem_Substance_ID:
46506588

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02252

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)O[C@H]4CO)O[C@H]3CO)O[C@H]2CO)[C@@H](O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:56 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M24516

# Drug_Target_1_GenBank_ID_Protein:
151013

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
amyP

# Drug_Target_1_Gene_Sequence:
>1644 bp
ATGAGCCACATCCTGCGAGCCGCCGTATTGGCGGCGATGCTGTTGCCGTTGCCGTCCATG
GCCGATCAGGCCGGCAAGAGCCCCAACGCTGTGCGCTACCACGGCGGCGACGAAATCATT
CTCCAGGGCTTTCACTGGAACGTCGTCCGCGAAGCGCCCAACGACTGGTACAACATCCTG
CGCCAGCAGGCCGCGACCATCGCCGCCGACGGCTTCTCGGCGATCTGGATGCCGGTGCCC
TGGCGCGACTTCTCCAGCTGGAGCGACGGCAGCAAGTCCGGCGGCGGTGAAGGCTACTTC
TGGCACGACTTCAACAAGAACGGCCGCTATGGCAGTGACGCCCAGCTGCGTCAGGCCGCC
AGCGCGCTCGGTGGCGCCGGCGTGAAAGTGCTTTACGACGTGGTGCCCAACCACATGAAC
CGTGGCTATCCGGACAAGGAGATCAACCTCCCGGCCGGCCAGGGCTTCTGGCGCAACGAC
TGCGCCGACCCGGGCAACTACCCCAATGATTGCGACGACGGCGACCGCTTCATCGGCGGC
GATGCGGACCTCAACACCGGCCACCCGCAGGTCTACGGCATGTTCCGCGATGAATTCACC
AACCTGCGCAGTCAGTACGGTGCCGGCGGCTTCCGCTTCGACTTTGTTCGGGGCTATGCG
CCGGAGCGGGTCAACAGCTGGATGACCGATAGCGCCGACAACAGCTTCTGCGTCGGCGAA
CTGTGGAAAGGCCCCTCTGAGTACCCGAACTGGGACTGGCGCAACACCGCCAGCTGGCAG
CAGATCATCAAGGACTGGTCCGACCGGGCCAAGTGCCCGGTGTTCGACTTCGCCCTCAAG
GAACGCATGCAGAACGCTCGATCGCCGACTGGAAGCACGCCTGAACGGCAATCCCGACCC
GCGTGGCGCGAGGTGGCGGTGACCTTCGTCGACAACCACGACACCGGCTACTCGCCCGGG
CAGAACGGTGGGCAGCACCACTGGGCTCTGCAGGACGGGCTGATCCGCCAGGCCTACGCC
TACATCCTCACCAGCCCCGGTACGCCGGTGGTGTACTGGTCGCACATGTACGACTGGGGT
TACGGCGACTTCATCCGTCAGCTGATCCAGGTGCGTCGCGCCGCCGGCGTGCGCGCCGAT
TCGGCGATCAGCTTCCACAGCGGCTACAGCGGTCTGGTCGCCACCGTCAGCGGCAGCCAG
CAGACCCTGGTGGTGGCGCTCAACTCCGACCTGGGCAATCCCGGCCAGGTGGCCAGCGGC
AGCTTCAGCGAGGCGGTCAACGCCAGCAACGGCCAGGTGCGCGTGTGGCGTAGCGGCACG
GGCAGCGGTGGCGGTGAACCCGGCGCTCTGGTCAGTGTGAGTTTCCGCTGCGACAACGGC
GCGACGCAGATGGGCGACAGCGTCTACGCGGTCGGCAACGTCAGCCAGCTCGGTAACTGG
AGCCCGGCCGCGGCGTTGCGCCTGACCGACACCAGCGGCTACCCGACCTGGAAGGGCAGC
ATTGCCTTGCCTGCCGGCCAGAACGAGGAATGGAAATGCCTGATCCGCAACGAGGCCAAC
GCCACCCAGGTGCGGCAATGGCAGGGCGGGGCAAACAACAGCCTGACGCCGAGCGAGGGC
GCCACCACCGTCGGCCGGCTCTAG

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
10556241	Hasegawa K, Kubota M, Matsuura Y: Roles of catalytic residues in alpha-amylases as evidenced by the structures of the product-complexed mutants of a maltotetraose-forming amylase. Protein Eng. 1999 Oct;12(10):819-24.
2646279	Fujita M, Torigoe K, Nakada T, Tsusaki K, Kubota M, Sakai S, Tsujisaka Y: Cloning and nucleotide sequence of the gene (amyP) for maltotetraose-forming amylase from Pseudomonas stutzeri MO-19. J Bacteriol. 1989 Mar;171(3):1333-9.
9126844	Morishita Y, Hasegawa K, Matsuura Y, Katsube Y, Kubota M, Sakai S: Crystal structure of a maltotetraose-forming exo-amylase from Pseudomonas stutzeri. J Mol Biol. 1997 Apr 4;267(3):661-72.
9281429	Yoshioka Y, Hasegawa K, Matsuura Y, Katsube Y, Kubota M: Crystal structures of a mutant maltotetraose-forming exo-amylase cocrystallized with maltopentaose. J Mol Biol. 1997 Aug 29;271(4):619-28.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2728

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
59876

# Drug_Target_1_Name:
Glucan 1,4-alpha-maltotetraohydrolase

# Drug_Target_1_Number_of_Residues:
548

# Drug_Target_1_PDB_ID:
1GCY

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF00686	CBM_20
PF09081	DUF1921

# Drug_Target_1_Protein_Sequence:
>Glucan 1,4-alpha-maltotetraohydrolase precursor
MSHILRAAVLAAMLLPLPSMADQAGKSPNAVRYHGGDEIILQGFHWNVVREAPNDWYNIL
RQQAATIAADGFSAIWMPVPWRDFSSWSDGSKSGGGEGYFWHDFNKNGRYGSDAQLRQAA
SALGGAGVKVLYDVVPNHMNRGYPDKEINLPAGQGFWRNDCADPGNYPNDCDDGDRFIGG
DADLNTGHPQVYGMFRDEFTNLRSQYGAGGFRFDFVRGYAPERVNSWMTDSADNSFCVGE
LWKGPSEYPNWDWRNTASWQQIIKDWSDRAKCPVFDFALKERMQNGSIADWKHGLNGNPD
PRWREVAVTFVDNHDTGYSPGQNGGQHHWALQDGLIRQAYAYILTSPGTPVVYWSHMYDW
GYGDFIRQLIQVRRAAGVRADSAISFHSGYSGLVATVSGSQQTLVVALNSDLGNPGQVAS
GSFSEAVNASNGQVRVWRSGTGSGGGEPGALVSVSFRCDNGATQMGDSVYAVGNVSQLGN
WSPAAALRLTDTSGYPTWKGSIALPAGQNEEWKCLIRNEANATQVRQWQGGANNSLTPSE
GATTVGRL

# Drug_Target_1_Reaction:
Hydrolysis of 1,4-alpha-D-glucosidic linkages in amylaceous polysaccharides, to remove successive maltotetraose residues from the non-reducing chain ends

# Drug_Target_1_Signals:
1-21

# Drug_Target_1_Specific_Function:
Hydrolysis of 1,4-alpha-D-glucosidic linkages in amylaceous polysaccharides, to remove successive maltotetraose residues from the non-reducing chain ends

# Drug_Target_1_SwissProt_ID:
P13507

# Drug_Target_1_SwissProt_Name:
AMT4_PSEST

# Drug_Target_1_Synonyms:
EC 3.2.1.60
Exo-maltotetraohydrolase
G4- amylase
Glucan 1,4-alpha-maltotetraohydrolase precursor
Maltotetraose-forming amylase
Maltotetraose-forming exo-amylase

# Drug_Target_1_Theoretical_pI:
5.93

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
D13178

# Drug_Target_2_GenBank_ID_Protein:
398125

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
tvaII

# Drug_Target_2_Gene_Sequence:
>1758 bp
ATGCTGTTGGAAGCGATTTTTCATGAAGCGAAAGGAAGCTATGCTTACCCGATTTCGGAA
ACGCAACTGCGGGTGAGATTGCGGGCGAAAAAAGGGGACGTGGTGAGATGCGAGGTGCTC
TATGCGGACCGCTATGCTTCGCCGGAGGAAGAACTGGCACATGCACTTGCGGGCAAAGCA
GGGTCCGATGAGCGATTTGATTATTTTGAGGCTTTACTGGAATGTTCCACCAAACGGGTG
AAATACGTGTTTTTGTTGACAGGCCCACAAGGGGAGGCTGTTTATTTTGGCGAGACCGGT
TTTTCCGCCGAACGGTCTAAAGCGGGGGTGTTCCAATATGCTTACATCCACCGGAGCGAA
GTGTTTACGACACCGGAATGGGCAAAGGAGGCGGTGATCTACCAGATCTTTCCCGAACGT
TTTGCCAATGGGGATCCCAGCAATGATCCGCCGGGAACGGAACAATGGGCCAAAGACGCC
AGACCTCGGCACGACAGTTTTTACGGCGGAGATTTAAAGGGGGTGATCGACCGTTTGCCA
TATTTGGAGGAGTTGGGAGTGACGGCGCTTTATTTTACTCCCATTTTTGCTTCGCCGTCC
CATCACAAATATGATACAGCTGATTATTTGGCGATTGATCCGCAATTTGGGGATTTGCCC
ACCTTTCGGCGTTTGGTGGATGAAGCTCACCGGCGCGGGATCAAAATCATTTTGGATGCC
GTGTTTAACCATGCCGGAGATCAGTTTTTTGCGTTTCGGGATGTTCTGCAAAAGGGAGAA
CAGTCGCGATATAAGGATTGGTTTTTCATCGAGGATTTTCCCGTTTCCAAGACGTCAAGA
ACCAATTATGAAACCTTTGCCGTCCAAGTGCCGGCCATGCCCAAATTGCGGACGGAAAAT
CCGGAAGTGAAGGAATATTTGTTTGATGTCGCGCGATTTTGGATGGAGCAGGGGATCGAC
GGATGGAGACTGGATGTGGCCAATGAGGTGGATCACGCCTTTTGGCGCGAGTTTCGCCGC
CTTGTCAAATCCCTCAATCCCGACGCCTTGATTGTCGGAGAGATTTGGCATGACGCTTCC
GGCTGGCTGATGGGAGACCAATTTGATTCGGTGATGAATTATTTGTTTCGCGAGAGTGTG
ATCCGTTTTTTTGCCACGGGGGAGATCCATGCCGAAAGATTTGACGCCGAACTTACCCGG
GCCAGGATGCTTTATCCGGAACAGGCGGCACAAGGGTTATGGAACCTCCTCGACTCACAC
GATACGGAACGTTTTTTGACATCGTGTGGGGGGAATGAGGCGAAATTCCGCCTGGCTGTT
TTGTTTCAGATGACATACCTGGGGACGCCGCTGATTTATTACGGTGATGAGATCGGGATG
GCCGGAGCGACGGACCCGGATTGCCGGCGCCCGATGATATGGGAGGAAAAAGAGCAGAAC
CGCGGCTTGTTTGAGTTTTATAAGGAATTGATTCGCTTGCGCCATCGGCTGGCATCGCTC
ACCAGGGGAAATGTCCGGTCTTGGCATGCCGACAAACAAGCCAATCTTTATGCTTTTGTG
CGCACGGTTCAAGACCAACATGTCGGTGTGGTTCTCAATAATCGTGGCGAGAAGCAAACC
GTTTTGCTACAGGTGCCGGAATCGGGCGGAAAAACTTGGCTGGATTGTTTGACCGGAGAA
GAAGTGCATGGCAAACAAGGGCAACTGAAGCTGACACTTCGCCCTTACCAGGGAATGATT
CTCTGGAATGGCCGGTAG

# Drug_Target_2_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_2_General_References:
10222200	Kamitori S, Kondo S, Okuyama K, Yokota T, Shimura Y, Tonozuka T, Sakano Y: Crystal structure of Thermoactinomyces vulgaris R-47 alpha-amylase II (TVAII) hydrolyzing cyclodextrins and pullulan at 2.6 A resolution. J Mol Biol. 1999 Apr 16;287(5):907-21.
12051850	Kamitori S, Abe A, Ohtaki A, Kaji A, Tonozuka T, Sakano Y: Crystal structures and structural comparison of Thermoactinomyces vulgaris R-47 alpha-amylase 1 (TVAI) at 1.6 A resolution and alpha-amylase 2 (TVAII) at 2.3 A resolution. J Mol Biol. 2002 Apr 26;318(2):443-53.
7763540	Tonozuka T, Ohtsuka M, Mogi S, Sakai H, Ohta T, Sakano Y: A neopullulanase-type alpha-amylase gene from Thermoactinomyces vulgaris R-47. Biosci Biotechnol Biochem. 1993 Mar;57(3):395-401.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2606

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
67468

# Drug_Target_2_Name:
Neopullulanase 2

# Drug_Target_2_Number_of_Residues:
585

# Drug_Target_2_PDB_ID:
1VFK

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00128	Alpha-amylase
PF02903	Alpha-amylase_N

# Drug_Target_2_Protein_Sequence:
>Neopullulanase 2
MLLEAIFHEAKGSYAYPISETQLRVRLRAKKGDVVRCEVLYADRYASPEEELAHALAGKA
GSDERFDYFEALLECSTKRVKYVFLLTGPQGEAVYFGETGFSAERSKAGVFQYAYIHRSE
VFTTPEWAKEAVIYQIFPERFANGDPSNDPPGTEQWAKDARPRHDSFYGGDLKGVIDRLP
YLEELGVTALYFTPIFASPSHHKYDTADYLAIDPQFGDLPTFRRLVDEAHRRGIKIILDA
VFNHAGDQFFAFRDVLQKGEQSRYKDWFFIEDFPVSKTSRTNYETFAVQVPAMPKLRTEN
PEVKEYLFDVARFWMEQGIDGWRLDVANEVDHAFWREFRRLVKSLNPDALIVGEIWHDAS
GWLMGDQFDSVMNYLFRESVIRFFATGEIHAERFDAELTRARMLYPEQAAQGLWNLLDSH
DTERFLTSCGGNEAKFRLAVLFQMTYLGTPLIYYGDEIGMAGATDPDCRRPMIWEEKEQN
RGLFEFYKELIRLRHRLASLTRGNVRSWHADKQANLYAFVRTVQDQHVGVVLNNRGEKQT
VLLQVPESGGKTWLDCLTGEEVHGKQGQLKLTLRPYQGMILWNGR

# Drug_Target_2_Reaction:
Hydrolysis of pullulan to panose (6-alpha-D-glucosylmaltose)

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Hydrolyzes pullulan efficiently but only a small amount of starch. Endohydrolysis of 1,4-alpha-glucosidic linkages in pullulan to form panose. Cleaves also (1-6)-alpha-glucosidic linkages to form maltotriose

# Drug_Target_2_SwissProt_ID:
Q08751

# Drug_Target_2_SwissProt_Name:
NEPU2_THEVU

# Drug_Target_2_Synonyms:
Alpha-amylase II
EC 3.2.1.135
TVA II

# Drug_Target_2_Theoretical_pI:
5.89

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB02237
